Lotte Sønderbjerg
Chief Administrative Officer bij ASCENDIS PHARMA A/S
Vermogen: 280 874 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Lotte Sønderbjerg
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 35 | |
| Public Company | Pharmaceuticals: Major | 9 | |
| Subsidiary | Pharmaceuticals: Major | 9 | |
ACADIA Pharmaceuticals A/S
 ACADIA Pharmaceuticals A/S Miscellaneous Commercial ServicesCommercial Services Part of ACADIA Pharmaceuticals, Inc., ACADIA Pharmaceuticals A/S utilizes technology to fuel drug discovery and clinical development. The private company is based in Glostrup, Denmark. The Danish company was founded by Peter Høngaard Andersen.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Lotte Sønderbjerg via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ALLERGAN, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| AMGEN INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal General Counsel | |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| INTERMUNE INC | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
| RIGEL PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| HUMANIGEN, INC. | Biotechnology | Sales & Marketing Chairman | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Corporate Officer/Principal | |
NextWave Pharmaceuticals, Inc.
 NextWave Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree Masters Business Admin | |
| VESTAS WIND SYSTEMS A/S | Electrical Products | Director/Board Member Director/Board Member | |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Investment Trusts/Mutual Funds | Director/Board Member Chief Executive Officer | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | President Corporate Officer/Principal | |
| ALK-ABELLÓ A/S | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| The University of Chicago | College/University | Doctorate Degree Doctorate Degree | |
| University of California San Diego | College/University | Corporate Officer/Principal Doctorate Degree | |
| University of Illinois | College/University | Undergraduate Degree Doctorate Degree | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| University of Uppsala | College/University | Doctorate Degree Doctorate Degree | |
| Technical University of Denmark | College/University | Doctorate Degree Doctorate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| University of Southern Denmark | College/University | Undergraduate Degree Doctorate Degree | |
Zizzi ApS
 Zizzi ApS Apparel/Footwear RetailRetail Trade Ball ApS sells and distributes women's apparels through its retail stores. It offers clothing lines for women through its retail brands such as Zizzi, Culture, Pulz, and Educe. The company was founded by Richard Andersen in 1988 and is headquartered in Billund, Denmark. | Apparel/Footwear Retail | Chairman | |
PricewaterhouseCoopers (Denmark)
 PricewaterhouseCoopers (Denmark) Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., PricewaterhouseCoopers (Denmark) is a private company based in Hellerup, Denmark. | Miscellaneous Commercial Services | Corporate Officer/Principal Chairman | |
| Acadia Pharmaceuticals AB | Chief Executive Officer Chief Executive Officer | ||
| Astra Arcus AB | Corporate Officer/Principal Corporate Officer/Principal | ||
| ADOCIA | Pharmaceuticals: Major | Founder Director/Board Member | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ASCENDANT RESOURCES INC. | Other Metals/Minerals | Chief Executive Officer Chief Operating Officer | |
| Best Buy Group A/S | Chairman | ||
| AVALO THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| NUCANA PLC | Biotechnology | Director/Board Member Director/Board Member | |
| AUDENTES THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chairman Director of Finance/CFO | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INTRA-CELLULAR THERAPIES, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
| KALVISTA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CESSATECH A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Ascendis Pharma Bone Diseases A/S | Chief Executive Officer Chairman | ||
| Ascendis Pharma Growth Disorders AS | Chief Executive Officer Chairman | ||
VISEN Pharmaceuticals
 VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member Chairman |
Statistieken
Internationaal
| Verenigde Staten | 21 |
| Denemarken | 19 |
| Zweden | 4 |
| Verenigd Koninkrijk | 3 |
| Zwitserland | 3 |
Sectoraal
| Health Technology | 28 |
| Consumer Services | 10 |
| Finance | 3 |
| Commercial Services | 3 |
| Miscellaneous | 3 |
Operationeel
| Director/Board Member | 316 |
| Corporate Officer/Principal | 121 |
| Chairman | 97 |
| Independent Dir/Board Member | 78 |
| Chief Executive Officer | 40 |
Sterkste connecties
| Insiders | |
|---|---|
| Torsten Erik Rasmussen | 55 |
| James Healy | 50 |
| Jonathan Silverstein | 42 |
| Albert Cha | 30 |
| Peter Andersen | 26 |
| Lars Holtug | 26 |
| Thomas Dyrberg | 24 |
| Michael Wolff Jensen | 23 |
| Jean Deleage | 23 |
| Rafaèle Elisabeth Tordjman | 23 |
| Martin Olin | 22 |
| Mark Brennan | 21 |
| Uli Alf Hacksell | 20 |
| Kurt Anker Nielsen | 18 |
| William Fairey | 15 |
- Beurs
- Insiders
- Lotte Sønderbjerg
- Bedrijfsconnecties
